COVID-19 Webcast Series

From the management of extended payment terms and performance-based agreements, to the potential impact of the proposed 2021 Medicare rules and the impending shortages of immune globulin, wholesale suppliers discuss how the COVID-19 pandemic continues to affect the oncology supply chain, what is being done to help practices, and what challenges lie ahead. Read More ›

Although several of the financial indicators in oncology have recovered to pre-pandemic levels following dramatic declines that occurred earlier in the year, there are still significant challenges ahead. How will providers manage the backlog? What will happen to patients’ insurance coverage? How will oncology practices survive and thrive in a post–COVID-19 world? Read More ›

Initiatives to expand patient access programs, strategies to secure the supply chain, and updates on vaccine trials: leaders from top pharmaceutical manufacturers discussed their companies’ ongoing response to the worldwide pandemic in this AVBCC webcast. Read More ›

With many clinical trials on hold and COVID-19 studies the only new trials opening up, how are cancer researchers adapting to the new environment? Can lessons from COVID-19 facilitate improved clinical trial recruitment and retention in the future? Read More ›

Other anti-cancer agents with potential promise in COVID-19 include Janus kinase inhibitors, such as ruxolitinib (Jakafi) and tofacitinib (Xeljanz). “Robust preclinical and clinical data suggest their activity in hyper-inflammatory syndromes,” said Kevin O’Hayer, MD, PhD, Senior Director, Immuno-oncology, Incyte Corporation. Read More ›

When oncology practices, ranging from small community clinics to larger hospital-based programs, were required to adapt their systems virtually overnight in response to the COVID-19 health crisis, almost no one anticipated that these would be long-term changes. However, as September approaches with no end in sight, it has become clear that oncologists will need to adapt revenue cycle management to long-term pandemic-related changes. Read More ›

As many full-service hospitals and health systems remain overwhelmed due to the COVID-19 pandemic, community cancer providers have been able to offer certain services to patients that may not be available at other institutions. How have these providers adapted to meet patients’ changing needs, and how are they keeping their doors open under unprecedented pressure? Read More ›

From shuttered laboratory experiments and interrupted clinical trial enrollments to a “shadow curve” of delayed cancer diagnoses, comprehensive cancer centers and integrated delivery networks (IDNs) across the country continue to grapple with the fallout from COVID-19. Read More ›

One of the most significant questions for payers in the COVID-19 health ecosystem is, “Will reimbursement parity for telehealth services continue?” Leading representatives of major managed care organizations debate the prospects. Read More ›

Shortages, inventory management, and challenges of in-home care were just a few of the topics in AVBCC’s wide-ranging webinar on how COVID-19 is affecting oncology pharmacy. Read More ›